Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

- Rasmussen, Birgitte B., Regan, Meredith M., Braye, Stephen, Altermatt, Hans J., Gelber, Richard D., Castiglione-Gertsch, Monica, Goldhirsch, Aron, Gusterson, Barry A., Thürlimann, Beat, Coates, Alan S., Viale, Giuseppe, Lykkesfeldt, Anne E., Dell'Orto, Patrizia, Del Curto, Barbara, Henriksen, Katrine L., Mastropasqua, Mauro G., Price, Karen N., Méry, Eliane E., Lacroix-Triki, Magali

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group

- Viale, Giuseppe, Regan, Meredith M., Braye, Stephen, Grigolato, Piergiovanni, Rusca, Tiziana, Gelber, Richard D., Castiglione-Gertsch, Monica, Price, Karen N., Goldhirsch, Aron, Gusterson, Barry A., Coates, Alan S., Maiorano, Eugenio, Mastropasqua, Mauro G., Golouh, Rastko, Perin, Tiziana, Brown, Robert W., Kovacs, Aniko, Pillay, Komala, Ohlschlegel, Christian

Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

- Sonnenblick, Amir, Francis, Prudence A., Lluch, Ana, Gnant, Michael, Goldhirsch, Aron, Di Leo, Angelo, Barnadas, Agusti, Cortes-Funes, Hernan, Piccart, Martine, Crown, John, Azim Jr, Hatem A., de Azambuja, Evandro, Nordenskjold, Bo, Gutierez, Jorge, Quinaux, Emmanuel, Mastropasqua, Mauro G., Ameye, Lieveke, Anderson, Michael